May Health Welcomes Colby Holtshouse as New President and CEO in an Exciting Leadership Transition

Leadership Change at May Health

In a significant move within the medical device sector, May Health has announced the appointment of Colby Holtshouse as its new President and CEO. This transition signifies the company's commitment to advancing its groundbreaking Ovarian Rebalancing technology, a treatment designed specifically for women suffering from Polycystic Ovary Syndrome (PCOS).

May Health, which operates out of both Paris and California, has established itself as a clinical-stage medical device company focusing on innovative solutions for women's health. The new leadership comes at a crucial time as the company prepares to finalize the REBALANCE study, a pivotal investigational device exemption (IDE) clinical trial aimed at securing marketing authorization for its Ovarian Rebalancing procedure. This innovative treatment is particularly focused on restoring ovulation in women with PCOS, a significant cause of infertility.

Colby Holtshouse: A Seasoned Leader

Colby Holtshouse is not new to the challenges and opportunities presented in women’s health. Drawing from a successful career that includes executive roles at notable organizations such as Organon, Alydia Health, and Pelvalon, Holtshouse brings a wealth of experience in launching medical technologies that improve patient outcomes. Dr. Robert Auerbach, Chairman of May Health, expressed enthusiasm about Holtshouse’s appointment, emphasizing her extensive background in bringing novel technologies to market.

“I am delighted to have Colby join and lead the company as we look to complete the REBALANCE study,” said Dr. Auerbach. His confidence in Holtshouse suggests that her leadership will prove crucial in the company’s mission to deliver their innovative Ovarian Rebalancing procedure to women grappling with the fertility challenges posed by PCOS.

Ovarian Rebalancing: A New Hope

The Ovarian Rebalancing technology represents a first-of-its-kind approach to treating fertility issues arising from PCOS. This procedure employs ultrasound-guided techniques combined with radio frequency (RF) energy to target and ablate excessive androgen-producing ovarian tissue. By doing so, it aims to create a more regular ovulatory cycle, thereby helping women who have previously been resistant to oral ovulation medication.

The one-time, in-office procedure is designed for minimal patient discomfort and permits a same-day recovery, allowing women to quickly return to their normal activities. Holtshouse expressed excitement about leading May Health during this pivotal time, highlighting the robust results observed in previous clinical feasibility studies as a foundation for further research.

The Challenge of PCOS

Polycystic Ovary Syndrome is a prevalent endocrine disorder affecting approximately 10% of women of reproductive age. One of the major complications associated with PCOS is infertility, resulting from the inability to ovulate. The condition is characterized by hormonal imbalances, leading to issues such as irregular menstrual cycles, excessive hair growth, and significant health risks like Type 2 diabetes, heart disease, and stroke.

This multi-faceted nature of PCOS not only complicates treatment options but also reflects the urgent need for innovative solutions like those being developed at May Health. With Holtshouse at the helm, the company aims to pave the way for broader adoption of the Ovarian Rebalancing procedure, addressing a critical need in women's health care that has long been underserved.

Looking Ahead

The appointment of Holtshouse is a strategic move for May Health as it navigates the path toward bringing its Ovarian Rebalancing technology to the market. With a solid foundation laid in clinical studies and the backing of experienced leadership, both May Health and its stakeholders anticipate significant advancements in how PCOS and its related fertility issues are treated in the coming years.

For women affected by PCOS, there is hope on the horizon as May Health remains committed to addressing the complexities of this widespread condition through innovative medical solutions. As the REBALANCE study progresses, the outcomes could not only validate the technology but ultimately lead to a change in how providers approach treatment for infertility linked to PCOS.